CLIN CHEM LAB MED:多中心对Alinity hq血液分析仪性能评价

2020-02-04 MedSci MedSci原创

Alinity hq (Abbott)是一款新型高通量血液分析仪,通过采用光学原理对血细胞进行检测和计数。该仪器报告了29个参数,包括六部分的白细胞(WBC)差异。这项多中心研究的目的是评估Alinity hq的分析和临床表现。

Alinity hq (Abbott)是一款新型高通量血液分析仪,通过采用光学原理对血细胞进行检测和计数。该仪器报告了29个参数,包括六部分的白细胞(WBC)差异。这项多中心研究的目的是评估Alinity hq的分析和临床表现。

研究人员对全血计数(CBC)结果和形态学标记与CELL-DYN Sapphire (Abbott)结果和2×200细胞手工鉴别结果进行了比较,这些结果来自荷兰三个不同临床实验室的明确定义的患者群体的1473个全血样本。此外,还评估了运行内和实验室内的精度、线性、定量限度、结转和样品稳定性。对外部质量评估样本也进行了评估。

数据分析表明,除了嗜碱性粒细胞外,所有CBC参数的碱度hq结果与CELL-DYN蓝宝石的结果具有很好的一致性。Alinity hq WBC的鉴别结果与手工鉴别结果的一致性较高,与CELL-DYN Sapphire相比,与手工碱基结果的一致性较好。Alinity hq Blast flag的敏感度为57.6%,与CELL-DYN SapphireBlast Alert的敏感度为57.6%。当考虑≥5%的样本时,Alinity hq Blast flag的灵敏度为70.0%。分析结果表明,碱度总部的性能与最先进(SOTA)的性能特征一致。

因此,Alinity hq的分析和临床性能特点使其非常适合临床实验室使用。

原始出处:

Christiaan L. SlimBrigitte A. WeversMulticenter performance evaluation of the Abbott Alinity hq hematology analyzer

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1904010, encodeId=573d19040103f, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 24 19:39:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936577, encodeId=747219365e713, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 28 13:39:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444612, encodeId=0c631444612d5, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610220, encodeId=31e8161022035, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1904010, encodeId=573d19040103f, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 24 19:39:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936577, encodeId=747219365e713, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 28 13:39:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444612, encodeId=0c631444612d5, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610220, encodeId=31e8161022035, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1904010, encodeId=573d19040103f, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 24 19:39:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936577, encodeId=747219365e713, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 28 13:39:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444612, encodeId=0c631444612d5, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610220, encodeId=31e8161022035, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]
    2020-02-06 huagfeg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1904010, encodeId=573d19040103f, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 24 19:39:00 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936577, encodeId=747219365e713, content=<a href='/topic/show?id=ef0989249d3' target=_blank style='color:#2F92EE;'>#血液分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89249, encryptionId=ef0989249d3, topicName=血液分析)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Tue Jul 28 13:39:00 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444612, encodeId=0c631444612d5, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610220, encodeId=31e8161022035, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Feb 06 04:39:00 CST 2020, time=2020-02-06, status=1, ipAttribution=)]

相关资讯

国际多中心药物临床试验指南(试行)

国家食品药品监督管理总局2015年第2号一、背景  近年来,药物研发日益趋于全球化,用于药品注册的国际多中心药物临床试验,已经从人用药品注册技术要求国际协调会(ICH)区域拓展到非ICH区域。药物全球同步研发,是一种共享资源的开发模式,可以减少不必要的重复临床试验,缩短区域或国家间药品上市延迟,提高患者获得新药的可及性。境内申办者为融入国际市场,也越来越关注全球同步研发。  申办者要根据早期研

中山大学完成全球AI医生多中心随机对照研究

5月6日,记者从中山大学中山眼科中心获悉,该中心教授刘奕志、林浩添眼科人工智能团队牵头完成全球首个AI医生多中心随机对照研究,为探索人工智能临床转化和落地应用标准,迈出了至关重要的一步。

颅内多中心少突星形细胞瘤1例

患者,男性,25岁,因“18d前突发抽搐1次”入院。既往身体健康,否认高血压、糖尿病及家族疾病史。

多中心骨巨细胞瘤伴肝肺转移1例

多中心骨巨细胞瘤(MCGCT)指同一患者发生的多于一处、并被组织病理学证实的骨巨细胞瘤。骨巨细胞瘤多为单发病灶,作为其中一种类型,多中心骨巨细胞瘤极为罕见,其发病率不足骨巨细胞瘤患者的1%。目前关于多中心骨巨细胞瘤文献资料均以个案报道为主,缺少多中心大样本数据。笔者曾于2017年12月收治1例多中心骨巨细胞瘤合并肝肺转移患者,现将诊治过程报道如下。

多中心临床试验中心效应的统计分析

多中心临床试验可以在较短的时间内招募到足够的病例数,同时,来自多个中心的病例比来自单中心的病例有更好的代表性,从而使得结论的外推性更可靠。但时,由于各中心的试验条件未必完全相同,同一中心数据具有相似性,而不同中心则会存在异质性,这种现象称为“中心效应(center effect)”。中心效应往往不可避免,特别是当主要疗效评价指标出现中心效应时,如果统计处理不当,所得结论将会产生偏性。 对

J Hepatology:大型多中心回顾性研究:超声造影(CEUS)可鉴别肝硬化中的肝细胞癌

美国放射学会最近发布了一个方案(CEUS LI-RADS),对病灶的肝细胞癌(HCC)风险进行分类,这些病灶经超声造影(CEUS)检查评估。